The Link Between Weight Loss Injections and Alcohol Consumption
Alcohol abuse is a serious illness responsible for 2.6 million deaths annually. This accounts for 4.7 percent of all deaths worldwide, according to a publication by the European Association for the Study of Obesity.1 Treatment methods such as cognitive behavioral therapy can usually only help in the short term, as 70 percent of patients relapse within the first year. A new study now seems to confirm a previously suspected side effect of the so-called weight loss injections: They dampen the craving for alcohol.
It feels like half of Hollywood is injecting themselves, and Ozempic, Semaglutide, and similar drugs have long since reached mainstream society. These substances are known as GLP-1 receptor agonists, which not only regulate blood sugar levels and curb appetite but apparently also dampen addiction cravings. Initial studies on mice had already provided indications of this (FITBOOK reported).
Researchers at University College Dublin wanted to investigate further and recruited 262 adults for their study, of whom 188 completed it. The results were published in the journal 'Diabetes, Obesity and Metabolism.'2
The participants (79 percent women) all had a BMI over 27 at the start and were treated with either Semaglutide or Liraglutide. The average age was 49 years, and the average weight was 98 kilograms. They were divided into
Non-drinkers (31 people or 11.8 percent of the participants)
Occasional drinkers with less than 10 alcohol units per week (52 people or 18.8 percent of the participants)
Regular drinkers with more than 10 alcohol units per week (179 people or 68.4 percent of the participants)
An alcohol unit corresponds to eight grams of pure alcohol, which is equivalent to a small glass of beer, a small glass of wine, or a shot.
Four months later, the researchers took stock. None of the participants had increased their alcohol consumption. On the contrary, the reduction in alcohol consumption was statistically significant. The average consumption of 11.8 alcohol units per week dropped to 4.3. So, those who previously enjoyed 12 small drinks only reached for the glass about four times.
Heavy drinkers also benefited greatly. Their alcohol consumption dropped from a risky 23.2 units to 7.3 units per week. The reduction by about one-third is comparable to the effect of Nalmefene, a medication used to treat alcohol abuse, according to the study report. Additionally, participants lost an average of 7.7 kilograms.
The study analyzed differences between male and female participants regarding the reduction in alcohol consumption and found that these differences were not significant. The study also found a weak positive correlation between the reduction in alcohol consumption and weight loss.
Weight loss injections, specifically GLP-1 medications, seem to significantly reduce not only weight but also the craving for alcohol—and apparently without self-discipline. Patients report an 'effortless effect.' How is this possible? 'How exactly GLP-1 analogs reduce alcohol consumption is not yet fully understood,' says study leader Professor le Roux. 'They likely work by suppressing the craving for alcohol—in brain areas that lie outside our conscious will.' There, the medications apparently reduce dopamine release in response to alcohol.
The assumption that weight loss injections like Semaglutide or Liraglutide not only influence eating behavior but also the craving for alcohol was further strengthened by the study. However, there is no control group, and the researchers had to rely entirely on the self-reports of the participants. This can lead to recall bias and socially desirable responses. Additionally, the study period was relatively short at four months, and about 28 percent of participants were 'lost' during the study.
While the results clearly suggest that these medications could play a supportive role in treating alcohol abuse, the findings will only become clinically significant when randomized controlled studies with longer observation periods, control groups, and more objective measurement methods confirm the hypothesis. The study shows only an association, not causality.
European Association for the Study of Obesity. Weight-loss drugs cut alcohol intake by almost two-thirds, research in Ireland suggests (accessed May 12, 2025) ↩︎
O'Farrell, M, Almohaileb, F.I. le Roux, C.W. (2024). Glucagon-like peptide-1 analogues reduce alcohol intake, Diabetes, Obesity and Metabolism. ↩︎
The post The Link Between Weight Loss Injections and Alcohol Consumption appeared first on FITBOOK.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
We recently published . MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare stocks. MannKind Corporation (NASDAQ:MNKD)'s most recent milestone is its push to expand the use of its rapid-acting inhaled insulin, Afrezza, to pediatric patients. In August 2025, the company submitted a supplemental Biologics License Application to the FDA for use in children ages 4–17, supported by positive Phase 3 INHALE-1 trial results presented at major diabetes conferences. A regulatory decision is expected in Q4 2025. Clinical data from both pediatric (INHALE-1) and adult (INHALE-3) studies have reinforced Afrezza's efficacy and safety across age groups. These advances have also helped the business gain attention among investors looking at the best healthcare stocks. Beyond Afrezza, MannKind Corporation (NASDAQ:MNKD) is advancing its pipeline in respiratory and rare diseases. MNKD-101, an inhaled clofazimine for nontuberculous mycobacterial lung disease, is progressing ahead of schedule in its global Phase 3 ICoN-1 trial. MNKD-201, a therapy for idiopathic pulmonary fibrosis, is set to enter Phase 2 testing by the end of 2025. Copyright: nicoletaionescu / 123RF Stock Photo To support these initiatives, the business secured up to $500 million in non-dilutive financing from Blackstone in August 2025. This funding will accelerate the potential launch of pediatric Afrezza, expand its commercial capabilities, and advance its clinical programs. Together, these developments position MannKind Corporation (NASDAQ:MNKD) for growth in both diabetes care and specialty lung disease markets. While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
a day ago
- Yahoo
It's rude to ask if someone is taking Ozempic. Here's why.
There's a new kind of nosy parker on the rise in the United States, a person who thinks it's fine to blurt out 'Are you on Ozempic?' to those they barely know. This is probably a reflection of how many Americans are taking this class of medications known as GLP-1 inhibitors. Twelve percent of adults in the United States have taken them at some point, according to a 2024 KFF Health Tracking Poll, and prescriptions have soared every year in the past decade. This class of medications includes tirzepatide (brand names Zepbound and Mounjaro) and semaglutide (Wegovy and Ozempic), and I know numerous friends and colleagues who take one. They have been lifesavers for many people with Type 2 diabetes or who want to lose weight for medical reasons. As with other medications, like Botox, some thorny social dilemmas have followed: Is it rude to ask if someone is taking one? And what do you say if someone asks you that question? Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. (Full disclosure: I was prescribed a GLP-1 for a cluster of medical conditions: prediabetes, insulin resistance and cardiovascular disease.) I talked to two physicians who prescribe the meds, two well-known advice columnists and two dozen GLP-1 users for their take on the big etiquette questions on the table. Here's what I learned. - - - Is it okay to ask someone if they're taking a GLP-1 inhibitor? Two years ago, I reconnected with a former colleague who'd lost so much weight I barely recognized him. My first thought was, 'Did he have cancer' or 'Was something wrong?' Lucky me, he beat me to the punch by confiding that he'd been using Ozempic. While some of those on GLP-1 inhibitors say it doesn't bother them to be asked, Randy Jones, an author and podcast host, who is currently taking one, told me: 'I absolutely don't think people should be empowered to ask someone about their medications without an invitation to do so.' Lizzie Post, the great-great-granddaughter of etiquette guru Emily Post and co-president of the institute that bears her name, agrees, explaining the medications we take and the procedures we undergo are private. 'You don't walk up to a friend and ask if they're on Botox,' she says. Bottom line: Don't ask, mostly. (And it's probably a good idea to avoid speculating on social media about celebrities' mysterious weight loss, too. It's practically a sport for some people, but that doesn't make it okay.) - - - But I want to show I care. Isn't that a good reason? Not really. Context matters, and you may not have all the details to navigate that tricky conversation without being offensive. A friend of mine, a pastor who is in front of a large congregation every Sunday, lost 52 pounds in nine months. She says she's been asked by just about everybody at one point or another, how she lost weight. While she appreciates the well-wishers who say, 'You look great! Do you feel good?' she also would prefer that people didn't make that big a deal out of it. For example, some people seem compelled to comment on her body every time they see her. 'Are you buying a whole new wardrobe?' 'You've gotten so little.' That gets under her skin because 'I don't like having my body size be the most interesting thing about me in their eyes.' David Wiss, a registered dietitian nutritionist who is based in Los Angeles and counsels patients on issues of weight and mental health, says he recommends avoiding 'body talk' of any kind. 'Body sovereignty describes the freedom and autonomy to make choices about your own body and health,' he said. Carolyn Hax, the longtime Washington Post advice columnist, says that if you're just being nosy, there's no good way to ask. But if you've struggled with weight yourself or know someone well enough to believe you can ask without giving offense, frame your question that way. Otherwise, Hax suggests, 'If people look well, look happy, look great in that color, then by all means say that.' But don't comment on their bodies. Bottom line: As I've often said, if it's curiosity that's driving you, curb it. - - - How should I respond if someone asks me this question? Matt Hughes, a town commissioner in Hillsborough, North Carolina, told me he's hesitant to make the disclosure about using a GLP-1 because 'it's almost as if someone worked less hard to lose the weight,' he said. Even if that's not your intention, asking people if they are taking a GLP-1 might be mistaken for 'Ozempic shaming,' which is when people are criticized or judged for taking a drug to lose weight rather than relying on diet and exercise, even though lifestyle changes don't work for the vast majority of people. 'Weight stigma is deeply ingrained and almost unconscious,' said Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital. She reminded me that GLP-1s are treatments for medical conditions - just like those for high blood pressure, cancer or anything else - which can empower those to reply to intrusive queries by being direct, humorous or just deflecting the question. Some snappy responses I've heard include: - 'It's none of your business.' - 'I like to keep a little mystery.' - 'Who wants to know?' - And my personal favorite: 'My weight is really not that interesting.' Bottom line: It's no one's business but your own, and you don't need to discuss your prescriptions with anyone but your doctor. - - - Are there new rules for dinner parties or sharing a restaurant tab? People who start taking GLP-1s often experience major changes in appetite or have side effects like nausea, which can limit how much they want to eat. Some people find they are less interested in drinking alcohol as well. That means in social situations, you may not be able to eat or drink like you have in the past. If you're dining at a friend's house and can't eat as much as you used to, a simple 'no, thank you' should suffice - and a considerate host won't press the issue. When dining out, there's the age-old dilemma about splitting the check: 'I only had a salad. You had a steak.' Or, 'I don't drink alcohol, and you had three cocktails.' When someone is having smaller portions or fewer courses, splitting a check can be even more difficult. Hax reminds people 'to be mindful of fairness and not hide behind expediency to get the 'sober dieting vegans' to cover their champagne and lobster.' She also suggests 'reading the room,' which means sometimes you can get separate checks, or take half of your meal home, and sometimes you just overpay, for the pleasure of everyone's company. Post also has some specific strategies, like telling friends you dine with regularly: 'Hey guys, I'm eating a lot less these days. Is it okay if I get my own check?' Or offer to use check-sharing apps like Billr or Divvy so that all diners pay what they owe. When I host, I've started asking guests not only if they have any food allergies or preferences, but also: 'Is there anything else I need to know in preparing dinner?' That allows room for someone to let me know either that they're on a GLP-1, or simply that they're only able to eat certain amounts or types of food these days. For that reason, I'm also inclined to serve buffet style, letting everyone decide how much they want on their plate. Bottom line: Be prepared to communicate your needs ahead of time and don't pry for details if a friend's eating habits change. I've faced many well-meaning but intrusive questions myself, which is why I smiled when Hax told me: 'Too bad there isn't a GLP-1 for ignorance.' Related Content Ukraine scrambles to roll back Russian eastern advance as summit takes place Her dogs kept dying, and she got cancer. Then they tested her water. D.C.'s homeless begin to see the effects of Trump's crackdown Solve the daily Crossword
Washington Post
2 days ago
- Washington Post
It's rude to ask if someone is taking Ozempic. Here's why.
There's a new kind of nosy parker on the rise in the United States, a person who thinks it's fine to blurt out 'Are you on Ozempic?' to those they barely know. This is probably a reflection of how many Americans are taking this class of medications known as GLP-1 inhibitors. Twelve percent of adults in the United States have taken them at some point, according to a 2024 KFF Health Tracking Poll, and prescriptions have soared every year in the past decade. This class of medications includes tirzepatide (brand names Zepbound and Mounjaro) and semaglutide (Wegovy and Ozempic), and I know numerous friends and colleagues who take one. They have been lifesavers for many people with Type 2 diabetes or who want to lose weight for medical reasons. As with other medications, like Botox, some thorny social dilemmas have followed: Is it rude to ask if someone is taking one? And what do you say if someone asks you that question? (Full disclosure: I was prescribed a GLP-1 for a cluster of medical conditions: prediabetes, insulin resistance and cardiovascular disease.) I talked to two physicians who prescribe the meds, two well-known advice columnists and two dozen GLP-1 users for their take on the big etiquette questions on the table. Here's what I learned. Two years ago, I reconnected with a former colleague who'd lost so much weight I barely recognized him. My first thought was, 'Did he have cancer' or 'Was something wrong?' Lucky me, he beat me to the punch by confiding that he'd been using Ozempic. While some of those on GLP-1 inhibitors say it doesn't bother them to be asked, Randy Jones, an author and podcast host, who is currently taking one, told me: 'I absolutely don't think people should be empowered to ask someone about their medications without an invitation to do so.' Lizzie Post, the great-great-granddaughter of etiquette guru Emily Post and co-president of the institute that bears her name, agrees, explaining the medications we take and the procedures we undergo are private. 'You don't walk up to a friend and ask if they're on Botox,' she says. Bottom line: Don't ask, mostly. (And it's probably a good idea to avoid speculating on social media about celebrities' mysterious weight loss, too. It's practically a sport for some people, but that doesn't make it okay.) Not really. Context matters, and you may not have all the details to navigate that tricky conversation without being offensive. A friend of mine, a pastor who is in front of a large congregation every Sunday, lost 52 pounds in nine months. She says she's been asked by just about everybody at one point or another, how she lost weight. While she appreciates the well-wishers who say, 'You look great! Do you feel good?' she also would prefer that people didn't make that big a deal out of it. For example, some people seem compelled to comment on her body every time they see her. 'Are you buying a whole new wardrobe?' 'You've gotten so little.' That gets under her skin because 'I don't like having my body size be the most interesting thing about me in their eyes.' David Wiss, a registered dietitian nutritionist who is based in Los Angeles and counsels patients on issues of weight and mental health, says he recommends avoiding 'body talk' of any kind. 'Body sovereignty describes the freedom and autonomy to make choices about your own body and health,' he said. Carolyn Hax, the longtime Washington Post advice columnist, says that if you're just being nosy, there's no good way to ask. But if you've struggled with weight yourself or know someone well enough to believe you can ask without giving offense, frame your question that way. Otherwise, Hax suggests, 'If people look well, look happy, look great in that color, then by all means say that.' But don't comment on their bodies. Bottom line: As I've often said, if it's curiosity that's driving you, curb it. Matt Hughes, a town commissioner in Hillsborough, North Carolina, told me he's hesitant to make the disclosure about using a GLP-1 because 'it's almost as if someone worked less hard to lose the weight,' he said. Even if that's not your intention, asking people if they are taking a GLP-1 might be mistaken for 'Ozempic shaming,' which is when people are criticized or judged for taking a drug to lose weight rather than relying on diet and exercise, even though lifestyle changes don't work for the vast majority of people. 'Weight stigma is deeply ingrained and almost unconscious,' said Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital. She reminded me that GLP-1s are treatments for medical conditions — just like those for high blood pressure, cancer or anything else — which can empower those to reply to intrusive queries by being direct, humorous or just deflecting the question. Some snappy responses I've heard include: Bottom line: It's no one's business but your own, and you don't need to discuss your prescriptions with anyone but your doctor. People who start taking GLP-1s often experience major changes in appetite or have side effects like nausea, which can limit how much they want to eat. Some people find they are less interested in drinking alcohol as well. That means in social situations, you may not be able to eat or drink like you have in the past. If you're dining at a friend's house and can't eat as much as you used to, a simple 'no, thank you' should suffice — and a considerate host won't press the issue. When dining out, there's the age-old dilemma about splitting the check: 'I only had a salad. You had a steak.' Or, 'I don't drink alcohol, and you had three cocktails.' When someone is having smaller portions or fewer courses, splitting a check can be even more difficult. Hax reminds people 'to be mindful of fairness and not hide behind expediency to get the 'sober dieting vegans' to cover their champagne and lobster.' She also suggests 'reading the room,' which means sometimes you can get separate checks, or take half of your meal home, and sometimes you just overpay, for the pleasure of everyone's company. Post also has some specific strategies, like telling friends you dine with regularly: 'Hey guys, I'm eating a lot less these days. Is it okay if I get my own check?' Or offer to use check-sharing apps like Billr or Divvy so that all diners pay what they owe. When I host, I've started asking guests not only if they have any food allergies or preferences, but also: 'Is there anything else I need to know in preparing dinner?' That allows room for someone to let me know either that they're on a GLP-1, or simply that they're only able to eat certain amounts or types of food these days. For that reason, I'm also inclined to serve buffet style, letting everyone decide how much they want on their plate. Bottom line: Be prepared to communicate your needs ahead of time and don't pry for details if a friend's eating habits change. I've faced many well-meaning but intrusive questions myself, which is why I smiled when Hax told me: 'Too bad there isn't a GLP-1 for ignorance.'
